NEW YORK – Chembio Diagnostics today announced that it has entered into a collaboration with Shire Human Genetic Therapies, a subsidiary of Takeda Pharmaceutical, to develop a quantitative point-of-care diagnostic test to detect an undisclosed biomarker.

Under the terms of the agreement, Medford, New York-based Chembio will receive funding from Takeda subject to satisfying certain milestones to develop a test that leverages Chembio's Dual-Path Platform (DPP) chromatographic immunoassay and hand-held optical analyzer.